{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:40:14Z","timestamp":1792809614410,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40123-026-01510-1","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:23:19Z","timestamp":1791206599000},"page":"3833-3850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Real-World Outcomes of Intravitreal Aflibercept 8\u00a0mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Jules","family":"Fricker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Sejournet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Prange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Rougane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9gol\u00e8ne","family":"Gouze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambre","family":"Ancel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Nicoara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Desmangles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3908-6716","authenticated-orcid":false,"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"1510_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106-116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1.","journal-title":"Lancet Glob Health"},{"key":"1510_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011.","journal-title":"Ophthalmology"},{"key":"1510_CR3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344. https:\/\/doi.org\/10.1056\/NEJMoa062655.","journal-title":"N Engl J Med"},{"key":"1510_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaophthalmol.2019.4557","volume":"138","author":"K Mulligan","year":"2020","unstructured":"Mulligan K, Seabury SA, Dugel PU, et al. Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States. JAMA Ophthalmol. 2020;138:40\u20137. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.4557.","journal-title":"JAMA Ophthalmol"},{"key":"1510_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29:721\u201331. https:\/\/doi.org\/10.1038\/eye.2015.48.","journal-title":"Eye (Lond)"},{"key":"1510_CR6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1.","journal-title":"Lancet"},{"key":"1510_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ophtha.2025.08.022","volume":"133","author":"J-F Korobelnik","year":"2026","unstructured":"Korobelnik J-F, Lanzetta P, Leal S, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration: ninety-six-week results from the randomized phase 3 PULSAR trial. Ophthalmology. 2026;133:39\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2025.08.022.","journal-title":"Ophthalmology"},{"key":"1510_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40123-025-01305-w","volume":"15","author":"G Grimaldi","year":"2026","unstructured":"Grimaldi G, Bartolomeo N, Garweg JG, et al. One-year real-world outcomes of aflibercept 8 mg in treatment-na\u00efve neovascular age-related macular degeneration: a Swiss Retina Research Network report. Ophthalmol Ther. 2026;15:1069\u201382. https:\/\/doi.org\/10.1007\/s40123-025-01305-w.","journal-title":"Ophthalmol Ther"},{"key":"1510_CR9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40123-026-01344-x","volume":"15","author":"AM Kitay","year":"2026","unstructured":"Kitay AM, Tillmann A, Pfister I, et al. One-year real-world outcomes of switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration: a Swiss Retina Research Network report. Ophthalmol Ther. 2026;15:1375\u201388. https:\/\/doi.org\/10.1007\/s40123-026-01344-x.","journal-title":"Ophthalmol Ther"},{"key":"1510_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/aos.17590","volume":"104","author":"I Abu Ishkheidem","year":"2026","unstructured":"Abu Ishkheidem I, Inci E, Breimer M, et al. Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration. Acta Ophthalmol. 2026;104:296\u2013304. https:\/\/doi.org\/10.1111\/aos.17590.","journal-title":"Acta Ophthalmol"},{"key":"1510_CR11","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S596218","volume":"20","author":"R Mizuma","year":"2026","unstructured":"Mizuma R, Mizuki Y, Kamata A, et al. One-year real-world outcomes of intravitreal aflibercept 8 mg for neovascular age-related macular degeneration in Japan: a multicenter retrospective study. Clin Ophthalmol. 2026;20:596218. https:\/\/doi.org\/10.2147\/OPTH.S596218.","journal-title":"Clin Ophthalmol"},{"key":"1510_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127:616\u201336. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004.","journal-title":"Ophthalmology"},{"key":"1510_CR13","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1001\/jamaophthalmol.2020.3989","volume":"138","author":"RP Finger","year":"2020","unstructured":"Finger RP, Puth M-T, Schmid M, et al. Lifetime outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. JAMA Ophthalmol. 2020;138:1234\u201340. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.3989.","journal-title":"JAMA Ophthalmol"},{"key":"1510_CR14","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","volume":"13","author":"G Cancian","year":"2024","unstructured":"Cancian G, Paris A, Agliati L, et al. One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration. Ophthalmol Ther. 2024;13:2985\u201397. https:\/\/doi.org\/10.1007\/s40123-024-01036-4.","journal-title":"Ophthalmol Ther"},{"key":"1510_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik J-F, Devenyi R, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina. 2015;35:1489\u2013506. https:\/\/doi.org\/10.1097\/IAE.0000000000000627.","journal-title":"Retina"},{"key":"1510_CR16","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2024.12.018","volume":"132","author":"GA Vemulakonda","year":"2025","unstructured":"Vemulakonda GA, Bailey ST, Kim SJ, et al. Age-related macular degeneration preferred practice pattern\u00ae. Ophthalmology. 2025;132:P1\u201374. https:\/\/doi.org\/10.1016\/j.ophtha.2024.12.018.","journal-title":"Ophthalmology"},{"key":"1510_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41433-026-04260-3","volume":"40","author":"C Bailey","year":"2026","unstructured":"Bailey C, Lange C, Chaudhary V, et al. SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration. Eye (Lond). 2026;40:735\u20138. https:\/\/doi.org\/10.1038\/s41433-026-04260-3.","journal-title":"Eye (Lond)"},{"key":"1510_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/24741264261423302","author":"M Shiratori","year":"2026","unstructured":"Shiratori M, Maruyama-Inoue M, Yanagi Y, et al. Comparison of short-term outcomes between faricimab and high-dose aflibercept in patients with neovascular age-related macular degeneration. J Vitreoretin Dis. 2026. https:\/\/doi.org\/10.1177\/24741264261423302.","journal-title":"J Vitreoretin Dis"},{"key":"1510_CR19","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1007\/s40123-025-01239-3","volume":"14","author":"N Bartolomeo","year":"2025","unstructured":"Bartolomeo N, Schuetz YP, Nascimbeni AC, et al. Early outcome analysis of intravitreal aflibercept 8 mg treatment in na\u00efve patients with neovascular age-related macular degeneration using artificial intelligence. Ophthalmol Ther. 2025;14:2819\u201329. https:\/\/doi.org\/10.1007\/s40123-025-01239-3.","journal-title":"Ophthalmol Ther"},{"key":"1510_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.70099","author":"ZG Angus","year":"2026","unstructured":"Angus ZG, Lee Y-Z, Sandhu SS, et al. Switching to faricimab or high-dose aflibercept for neovascular AMD in high-demand patients: impact on injection interval in a real-world cohort. Clin Exp Ophthalmol. 2026. https:\/\/doi.org\/10.1111\/ceo.70099.","journal-title":"Clin Exp Ophthalmol"},{"key":"1510_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40123-026-01320-5","volume":"15","author":"N Bartolomeo","year":"2026","unstructured":"Bartolomeo N, Kalyvianakis KK, Schuetz YP, et al. Early outcomes of intravitreal aflibercept 8 mg in eyes previously treated with aflibercept 2 mg for neovascular age-related macular degeneration with AI-based biomarker quantification. Ophthalmol Ther. 2026;15:831\u201342. https:\/\/doi.org\/10.1007\/s40123-026-01320-5.","journal-title":"Ophthalmol Ther"},{"key":"1510_CR22","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1007\/s40123-025-01247-3","volume":"14","author":"SM Friedman","year":"2025","unstructured":"Friedman SM, Xu Y, Sherman S, et al. Aflibercept 8 mg versus faricimab treat-and-extend for diabetic macular edema or neovascular age-related macular degeneration: a Bayesian fixed-effect network meta-analysis of clinical trials. Ophthalmol Ther. 2025;14:2919\u201336. https:\/\/doi.org\/10.1007\/s40123-025-01247-3.","journal-title":"Ophthalmol Ther"},{"key":"1510_CR23","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41433-026-04425-0","volume":"40","author":"IK Janmohamed","year":"2026","unstructured":"Janmohamed IK, Harahn H, Carr B, et al. Early real-world outcomes of aflibercept 8 mg in previously treated neovascular age-related macular degeneration. Eye (Lond). 2026;40:1351\u20137. https:\/\/doi.org\/10.1038\/s41433-026-04425-0.","journal-title":"Eye (Lond)"},{"key":"1510_CR24","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41433-022-02231-y","volume":"37","author":"T Mathis","year":"2023","unstructured":"Mathis T, Holz FG, Sivaprasad S, et al. Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye (Lond). 2023;37:1758\u201365. https:\/\/doi.org\/10.1038\/s41433-022-02231-y.","journal-title":"Eye (Lond)"},{"key":"1510_CR25","first-page":"2224","volume":"64","author":"H Kang","year":"2023","unstructured":"Kang H, Lains I, Nigalye A, et al. Predictors of treatment response after intravitreal anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2023;64:2224\u20132224.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1510_CR26","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1007\/s40123-024-01021-x","volume":"13","author":"M Sagong","year":"2024","unstructured":"Sagong M, Kim JH, Woo SJ, et al. Predictors of disease activity after anti-VEGF treatment for neovascular age-related macular degeneration using real-world data from the PROOF study. Ophthalmol Ther. 2024;13:2839\u201353. https:\/\/doi.org\/10.1007\/s40123-024-01021-x.","journal-title":"Ophthalmol Ther"},{"key":"1510_CR27","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40123-026-01349-6","volume":"15","author":"L Hoffmann","year":"2026","unstructured":"Hoffmann L, Hatz K. Lower rates of intraocular inflammation with aflibercept 8 mg delivered via pre-filled syringe versus vial. Ophthalmol Ther. 2026;15:1499\u2013508. https:\/\/doi.org\/10.1007\/s40123-026-01349-6.","journal-title":"Ophthalmol Ther"},{"key":"1510_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2025.104583","volume":"48","author":"EH Souied","year":"2025","unstructured":"Souied EH, Couturier A, Devin F, et al. Functional and anatomic outcomes of brolucizumab in adults with neovascular age-related macular degeneration - the OCTOPUS cohort study. J Fr Ophtalmol. 2025;48:104583. https:\/\/doi.org\/10.1016\/j.jfo.2025.104583.","journal-title":"J Fr Ophtalmol"},{"key":"1510_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/24741264251383384","author":"BA Bates","year":"2025","unstructured":"Bates BA, Mansour HA, Al-Khersan H, et al. The efficacy and safety of intravitreal aflibercept 8 mg in clinical practice. J Vitreoretin Dis. 2025. https:\/\/doi.org\/10.1177\/24741264251383384.","journal-title":"J Vitreoretin Dis"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01510-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:03:28Z","timestamp":1792807408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01510-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1510"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01510-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"3 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jules Fricker, Lucas Sejournet, Jules Prange, Julien Andre, Remy Calvet, Valentin Rougane, S\u00e9gol\u00e8ne Gouze, Maxime Oudard, Ambre Ancel, Alexis Kodjikian, Simona Nicoara and Philippe Desmangles have no conflicts of interest to declare. Thibaud Mathis: Consultant for AbbVie, Bayer, GSK, Novartis, and Roche. Laurent Kodjikian: Consultant for AbbVie, Alimera, Horus, Bayer, Krys, Novartis, Roche, and Th\u00e9a.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all patients at the time of treatment collection, authorizing the use of their anonymized clinical data for research purposes. This study protocol was reviewed and approved by Hospices Civils de Lyon Ethics Committee, approval number 20\u2013156.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}